P2.06-001 A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors
Year: 2017
Type: article
Source: Journal of Thoracic Oncology
Authors: Theresa Werner, Rebecca Heist, Richard Carvajal, Douglas Adkins, Ajjai Alva, Sanjay Goel, David Hong, Lyudmila Bazhenova, Mansoor Saleh, Robert Siegel, Christos Kyriakopoulos, Collin Blakely, Keith Eaton, Richard Lauer, Ding Wang, Gary Schwartz, Saskia Neuteboom, Diane Potvin, Demiana Faltaos, Isan Chen, James Christensen, Matteo Levisetti, Richard Chao, Todd Bauer
Institutions: Huntsman Cancer Institute, Massachusetts General Hospital, Columbia University Irving Medical Center, Washington University in St. Louis, University of Michigan, Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of California San Diego, Moores Cancer Center, University of Alabama at Birmingham, University of Wisconsin–Madison, University of California, San Francisco, University of California San Francisco Medical Center, Seattle Cancer Care Alliance, University of Washington, UNM Comprehensive Cancer Center, Henry Ford Health, Mirati Therapeutics (United States), Tennessee Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2767241623